Kainos Medicine, Inc. (KOSDAQ:284620)
1,087.00
-105.00 (-8.81%)
At close: Aug 14, 2025
Kainos Medicine Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 2,866 | 3,834 | 16,337 | 24,952 | 23,231 |
Short-Term Investments | - | - | 79.85 | 5,000 | 11,000 |
Cash & Short-Term Investments | 2,866 | 3,834 | 16,417 | 29,952 | 34,231 |
Cash Growth | -25.24% | -76.64% | -45.19% | -12.50% | 14.82% |
Accounts Receivable | 255.33 | 252.77 | 83.75 | -0 | 0 |
Other Receivables | 36.26 | 62.53 | 4.35 | 295.7 | 290.89 |
Receivables | 291.58 | 490.3 | 88.1 | 295.7 | 290.89 |
Prepaid Expenses | 157.88 | 96.69 | 258.68 | 949.3 | 2,020 |
Other Current Assets | 1,094 | 182.94 | 353.43 | 38.45 | 331.12 |
Total Current Assets | 4,410 | 4,604 | 17,117 | 31,236 | 36,873 |
Property, Plant & Equipment | - | 602.75 | 875.47 | 5,437 | 3,334 |
Long-Term Investments | 2,138 | 3,503 | 786.56 | 740.63 | 642.79 |
Other Intangible Assets | - | 501.61 | 810.67 | 861.84 | 689.04 |
Long-Term Accounts Receivable | - | -0 | 0 | -0 | -0 |
Other Long-Term Assets | 70.15 | 1,531 | 1,395 | 707.04 | 418.79 |
Total Assets | 6,617 | 10,742 | 20,985 | 38,982 | 41,957 |
Accrued Expenses | 256.38 | 99.83 | 49.92 | 65.04 | 575.51 |
Short-Term Debt | - | - | - | 761.67 | 12,468 |
Current Portion of Long-Term Debt | - | - | - | 2,285 | - |
Current Portion of Leases | 147.28 | 355.37 | 352.17 | 550.74 | 276.27 |
Other Current Liabilities | 1,611 | 1,931 | 1,400 | 1,213 | 8,779 |
Total Current Liabilities | 2,014 | 2,386 | 1,802 | 4,876 | 22,099 |
Long-Term Debt | - | - | - | - | 1,523 |
Long-Term Leases | - | 135.91 | 48.66 | 314.34 | 103.95 |
Other Long-Term Liabilities | - | 33.75 | 36.62 | 73.8 | 73.92 |
Total Liabilities | 2,014 | 2,556 | 1,888 | 5,264 | 23,800 |
Common Stock | 16,543 | 14,090 | 13,961 | 13,961 | 11,029 |
Additional Paid-In Capital | 116,022 | 111,617 | 110,117 | 110,117 | 84,564 |
Retained Earnings | -136,389 | -128,605 | -116,414 | -101,179 | -85,298 |
Treasury Stock | -40.95 | -40.95 | -55.12 | -55.12 | -22.72 |
Comprehensive Income & Other | 5,012 | 4,726 | 4,143 | 3,266 | 1,831 |
Total Common Equity | 1,147 | 1,788 | 11,751 | 26,109 | 12,104 |
Minority Interest | 3,456 | 4,086 | 4,020 | 3,808 | 2,497 |
Shareholders' Equity | 4,603 | 8,186 | 19,098 | 33,719 | 18,157 |
Total Liabilities & Equity | 6,617 | 10,742 | 20,985 | 38,982 | 41,957 |
Total Debt | 147.28 | 491.29 | 400.83 | 3,912 | 14,372 |
Net Cash (Debt) | 2,719 | 3,343 | 16,016 | 26,040 | 19,859 |
Net Cash Growth | -18.66% | -79.13% | -38.50% | 31.12% | 7.24% |
Net Cash Per Share | 85.92 | 120.11 | 573.59 | 1092.41 | 937.14 |
Filing Date Shares Outstanding | 32.76 | 27.81 | 27.92 | 27.92 | 22.06 |
Total Common Shares Outstanding | 32.76 | 27.81 | 27.92 | 27.92 | 22.06 |
Working Capital | 2,395 | 2,218 | 15,315 | 26,360 | 14,774 |
Book Value Per Share | 35.01 | 64.30 | 420.94 | 935.25 | 548.77 |
Tangible Book Value | 1,147 | 1,286 | 10,941 | 25,247 | 11,414 |
Tangible Book Value Per Share | 35.01 | 46.26 | 391.90 | 904.38 | 517.53 |
Machinery | - | 743.51 | 760.19 | 749.6 | 725.66 |
Construction In Progress | - | - | - | 3,829 | 2,287 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.